MedTrace Logo

Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia

NCT02473016 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-11-17

No results posted yet for this study

Summary

A placebo-controlled, single-blind study to evaluate the safety and preliminary efficacy of nasal carbon dioxide for the symptomatic treatment of classical trigeminal neuralgia.

Conditions

  • Trigeminal Neuralgia

Interventions

DRUG

Carbon Dioxide Drug Delivery System (CDDS)

Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\].

Sponsors & Collaborators

  • Capnia, Inc.

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-03-31
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02473016 on ClinicalTrials.gov